Intriguingly, TRIM1 inhibits Rab29-mediated LRRK2 kinase activation (for both WT and PD-mutant R1441G LRRK2), and this effect is not due to decreased LRRK2 protein levels. This evidence concerns the gene RAB29 and Parkinson disease.